Why the study?
Does SAVR or TAVI reduce mortality in older adults with symptomatic severe calcific aortic stenosis?
Does SAVR or TAVI reduce mortality in older adults with symptomatic severe calcific aortic stenosis?
SAVR and TAVI are life-saving interventions for symptomatic severe calcific aortic stenosis, reducing mortality to match age-matched controls.
Answers are grounded in this paper and cite their sources.
Supports prompt SAVR or TAVI in symptomatic severe AS; leaves open optimal selection and timing in contemporary cohorts.
Calcific AS is a common chronic progressive condition among older adults and is diagnosed via echocardiography. Symptomatic patients with severe AS have a mortality rate of up to 50% after 1 year, but treatment with SAVR or TAVI reduces mortality to that of age-matched control patients. The type and timing of valve replacement should be built on evidence-based guidelines, shared decision-making, and involvement of a multidisciplinary heart valve team.
No takes yet. Share an insight, caveat, or question.
Otto et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: